ADA and pure red-cell aplasia: The original recombinant erythropoietin (EPO) drug (Epogen) was introduced in 1988 and has been used successfully worldwide; however, incidences of neutralising anti-EPO ADA have been reported with the development of pure red cell aplasia (PRCA).